Cucurbit[n]uril binding of platinum anticancer complexes.
The encapsulation of cisplatin by cucurbit[7]uril (Q[7]) and multinuclear platinum complexes linked via a 4,4'-dipyrazolylmethane (dpzm) ligand by Q[7] and cucurbit[8]uril (Q[8]) has been studied by NMR spectroscopy and molecular modelling. The NMR studies suggest that some cisplatin binds in the cucurbituril cavity, while cis-[PtCl(NH3)2(H2O)]+ only binds at the portals. Alternatively, the dpzm-linked multinuclear platinum complexes are quantitatively encapsulated within the cavities of both Q[7] and Q[8]. Upon encapsulation, the non-exchangeable proton resonances of the multinuclear platinum complexes show significant upfield shifts in 1H NMR spectra. The H3/H3* resonances shift upfield by 0.08 to 0.55 ppm, the H5/H5* shift by 0.9 to 1.6 ppm, while the methylene resonances shift by 0.74 to 0.88 ppm. The size of the resonance shift is dependent on the cavity size of the encapsulating cucurbituril, with Q[7] encapsulation producing larger shifts than Q[8]. The upfield shifts of the dpzm resonances observed upon cucurbituril encapsulation indicate that the Q[7] or Q[8] is positioned directly over the dpzm linking ligand. The terminal platinum groups of trans-[{PtCl(NH3)2}2 mu-dpzm]2+ (di-Pt) and trans-[trans-{PtCl(NH3)2}2-trans-{Pt(dpzm)2(NH3)2}]4+ (tri-Pt) provide a barrier to the on and off movement of cucurbituril, resulting in binding kinetics that are slow on the NMR timescale for the metal complex. Although the dpzm ligand has relatively few rotamers, encapsulation by the larger Q[8] resulted in a more compact di-Pt conformation with each platinum centre retracted further into each Q[8] portal. Encapsulation of the hydrolysed forms of di-Pt and tri-Pt is considerably slower than for the corresponding Cl forms, presumably due to the high-energy cost of passing the +2 platinum centres through the cucurbituril portals. The results of this study suggest that cucurbiturils could be suitable hosts for the pharmacological delivery of multinuclear platinum complexes.
Wheate
Nial J
NJ
School of Physical, Environmental and Mathematical Sciences, University College, University of New South Wales, Australian Defence Force Academy, Canberra, ACT 2600, Australia.
Buck
Damian P
DP
Day
Anthony I
AI
Collins
J Grant
JG
D000970:Antineoplastic Agents / Q000494:pharmacology*; D040761:Biomimetic Materials / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000737:chemistry* / Q000494:pharmacology; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology; D004337:Drug Carriers / Q000494:pharmacology*; D007093:Imidazoles / Q000737:chemistry* / Q000494:pharmacology; D007700:Kinetics; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008697:Methane / Q000031:analogs & derivatives / Q000737:chemistry; D015394:Molecular Structure; D017671:Platinum Compounds / Q000737:chemistry*; D011720:Pyrazoles / Q000737:chemistry; D047028:Macrocyclic Compounds; D000099246:Cucurbit(n)urils
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D002945:Cisplatin; D004337:Drug Carriers; D007093:Imidazoles; D008024:Ligands; D008697:Methane; D017671:Platinum Compounds; D011720:Pyrazoles; C493313:4,4'-dipyrazolylmethane; C456276:cucurbit(7)uril; D047028:Macrocyclic Compounds; D000099246:Cucurbit(n)urils; C507198:cucurbit(8)uril